Cargando…

The effects of first-line anti-tuberculosis drugs on the actions of vitamin D in human macrophages

Tuberculosis (TB) is a major global health problem. Patients with TB have a high rate of vitamin D deficiency, both at diagnosis and during the course of treatment with anti-tuberculosis drugs. Although data on the efficacy of vitamin D supplementation on Mycobacterium tuberculosis (Mtb) clearance a...

Descripción completa

Detalles Bibliográficos
Autores principales: Chesdachai, Supavit, Zughaier, Susu M., Hao, Li, Kempker, Russell R., Blumberg, Henry M., Ziegler, Thomas R., Tangpricha, Vin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5242622/
https://www.ncbi.nlm.nih.gov/pubmed/28111615
http://dx.doi.org/10.1016/j.jcte.2016.08.005
_version_ 1782496365667942400
author Chesdachai, Supavit
Zughaier, Susu M.
Hao, Li
Kempker, Russell R.
Blumberg, Henry M.
Ziegler, Thomas R.
Tangpricha, Vin
author_facet Chesdachai, Supavit
Zughaier, Susu M.
Hao, Li
Kempker, Russell R.
Blumberg, Henry M.
Ziegler, Thomas R.
Tangpricha, Vin
author_sort Chesdachai, Supavit
collection PubMed
description Tuberculosis (TB) is a major global health problem. Patients with TB have a high rate of vitamin D deficiency, both at diagnosis and during the course of treatment with anti-tuberculosis drugs. Although data on the efficacy of vitamin D supplementation on Mycobacterium tuberculosis (Mtb) clearance are uncertain from randomized controlled trials (RCTs), vitamin D enhances the expression of the anti-microbial peptide human cathelicidin (hCAP18) in cultured macrophages in vitro. One possible explanation for the mixed (primarily negative) results of RCTs examining vitamin D treatment in TB infection is that anti-TB drugs given to enrolled subjects may impact actions of vitamin D to enhance cathelicidin in macrophages. To address this hypothesis, human macrophage-like monocytic (THP-1) cells were treated with varying doses of first-line anti-tuberculosis drugs in the presence of the active form of vitamin D, 1,25-dihydroxyvitamin D(3) (1,25(OH)(2)D(3)). The expression of hCAP18 was determined by quantitative reverse transcriptase polymerase chain reaction (qRT-PCR). 1,25(OH)(2)D(3) strongly induced expression of hCAP18 mRNA in THP-1 cells (fold-change from control). The combination of the standard 4-drug TB therapy (isoniazid, rifampicin, pyrazinamide and ethambutol) in the cultured THP-1 cells demonstrated a significant decrease in hCAP18 mRNA at the dosage of 10 µg/mL. In 31 subjects with newly diagnosed drug-sensitive TB randomized to either high-dose vitamin D(3) (1.2 million IU over 8 weeks, n = 13) versus placebo (n = 18), there was no change from baseline to week 8 in hCAP18 mRNA levels in peripheral blood mononuclear cells or in plasma concentrations of LL-37, the protein product of hCAP18. These data suggest that first-line anti-TB drugs may alter the vitamin D-dependent increase in hCAP18 and LL-37 human macrophages.
format Online
Article
Text
id pubmed-5242622
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-52426222017-10-24 The effects of first-line anti-tuberculosis drugs on the actions of vitamin D in human macrophages Chesdachai, Supavit Zughaier, Susu M. Hao, Li Kempker, Russell R. Blumberg, Henry M. Ziegler, Thomas R. Tangpricha, Vin J Clin Transl Endocrinol Research Paper Tuberculosis (TB) is a major global health problem. Patients with TB have a high rate of vitamin D deficiency, both at diagnosis and during the course of treatment with anti-tuberculosis drugs. Although data on the efficacy of vitamin D supplementation on Mycobacterium tuberculosis (Mtb) clearance are uncertain from randomized controlled trials (RCTs), vitamin D enhances the expression of the anti-microbial peptide human cathelicidin (hCAP18) in cultured macrophages in vitro. One possible explanation for the mixed (primarily negative) results of RCTs examining vitamin D treatment in TB infection is that anti-TB drugs given to enrolled subjects may impact actions of vitamin D to enhance cathelicidin in macrophages. To address this hypothesis, human macrophage-like monocytic (THP-1) cells were treated with varying doses of first-line anti-tuberculosis drugs in the presence of the active form of vitamin D, 1,25-dihydroxyvitamin D(3) (1,25(OH)(2)D(3)). The expression of hCAP18 was determined by quantitative reverse transcriptase polymerase chain reaction (qRT-PCR). 1,25(OH)(2)D(3) strongly induced expression of hCAP18 mRNA in THP-1 cells (fold-change from control). The combination of the standard 4-drug TB therapy (isoniazid, rifampicin, pyrazinamide and ethambutol) in the cultured THP-1 cells demonstrated a significant decrease in hCAP18 mRNA at the dosage of 10 µg/mL. In 31 subjects with newly diagnosed drug-sensitive TB randomized to either high-dose vitamin D(3) (1.2 million IU over 8 weeks, n = 13) versus placebo (n = 18), there was no change from baseline to week 8 in hCAP18 mRNA levels in peripheral blood mononuclear cells or in plasma concentrations of LL-37, the protein product of hCAP18. These data suggest that first-line anti-TB drugs may alter the vitamin D-dependent increase in hCAP18 and LL-37 human macrophages. Elsevier 2016-09-14 /pmc/articles/PMC5242622/ /pubmed/28111615 http://dx.doi.org/10.1016/j.jcte.2016.08.005 Text en http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Research Paper
Chesdachai, Supavit
Zughaier, Susu M.
Hao, Li
Kempker, Russell R.
Blumberg, Henry M.
Ziegler, Thomas R.
Tangpricha, Vin
The effects of first-line anti-tuberculosis drugs on the actions of vitamin D in human macrophages
title The effects of first-line anti-tuberculosis drugs on the actions of vitamin D in human macrophages
title_full The effects of first-line anti-tuberculosis drugs on the actions of vitamin D in human macrophages
title_fullStr The effects of first-line anti-tuberculosis drugs on the actions of vitamin D in human macrophages
title_full_unstemmed The effects of first-line anti-tuberculosis drugs on the actions of vitamin D in human macrophages
title_short The effects of first-line anti-tuberculosis drugs on the actions of vitamin D in human macrophages
title_sort effects of first-line anti-tuberculosis drugs on the actions of vitamin d in human macrophages
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5242622/
https://www.ncbi.nlm.nih.gov/pubmed/28111615
http://dx.doi.org/10.1016/j.jcte.2016.08.005
work_keys_str_mv AT chesdachaisupavit theeffectsoffirstlineantituberculosisdrugsontheactionsofvitamindinhumanmacrophages
AT zughaiersusum theeffectsoffirstlineantituberculosisdrugsontheactionsofvitamindinhumanmacrophages
AT haoli theeffectsoffirstlineantituberculosisdrugsontheactionsofvitamindinhumanmacrophages
AT kempkerrussellr theeffectsoffirstlineantituberculosisdrugsontheactionsofvitamindinhumanmacrophages
AT blumberghenrym theeffectsoffirstlineantituberculosisdrugsontheactionsofvitamindinhumanmacrophages
AT zieglerthomasr theeffectsoffirstlineantituberculosisdrugsontheactionsofvitamindinhumanmacrophages
AT tangprichavin theeffectsoffirstlineantituberculosisdrugsontheactionsofvitamindinhumanmacrophages
AT chesdachaisupavit effectsoffirstlineantituberculosisdrugsontheactionsofvitamindinhumanmacrophages
AT zughaiersusum effectsoffirstlineantituberculosisdrugsontheactionsofvitamindinhumanmacrophages
AT haoli effectsoffirstlineantituberculosisdrugsontheactionsofvitamindinhumanmacrophages
AT kempkerrussellr effectsoffirstlineantituberculosisdrugsontheactionsofvitamindinhumanmacrophages
AT blumberghenrym effectsoffirstlineantituberculosisdrugsontheactionsofvitamindinhumanmacrophages
AT zieglerthomasr effectsoffirstlineantituberculosisdrugsontheactionsofvitamindinhumanmacrophages
AT tangprichavin effectsoffirstlineantituberculosisdrugsontheactionsofvitamindinhumanmacrophages